Arie Belldegrun - Allogene Therapeutics Executive Chairman of the Board, Co-Founder
ALLO Stock | USD 3.46 0.05 1.42% |
Chairman
Dr. Arie S. Belldegrun, M.D., FACS, serves as Executive Chairman of the Board, CoFounder of the Company. He is a cofounder of Allogene and has served as Executive Chairman of our board of directors since November 2017. From March 2014 until October 2017 Dr. Belldegrun served as the President and Chief Executive Officer of Kite and as a director from June 2009 until October 2017. Dr. Belldegrun currently serves as Chairman of Urogen Pharma, Ltd., a position he has held since December 2012, as Chairman and Partner of Two River Consulting, LLC, a position he has held since June 2009, and as Chairman of the Board of Directors of Kronos Bio, Inc., a position that he has held since June 2017. Dr. Belldegrun has also served as Senior Managing Director of Vida Ventures, LLC since November 2017. Dr. Belldegrun previously served as a director of Teva Pharmaceutical Industries Ltd. from March 2013 until January 2017, Chairman of Arno Therapeutics, Inc. from March 2008 until January 2017, a director of Capricor Therapeutics, Inc. from September 2009 until November 2013, and a director of SonaCare Medical, LLC from October 2009 until October 2014. In 1996, he founded Agensys, Inc., a biotechnology company, where he served as its founding Chairman from 1996 to 2001, and continued to serve on the board until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding ViceChairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson Johnson. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr
Age | 68 |
Professional Marks | Ph.D |
Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Phone | 650 457 2700 |
Web | https://www.allogene.com |
Arie Belldegrun Latest Insider Activity
Tracking and analyzing the buying and selling activities of Arie Belldegrun against Allogene Therapeutics stock is an integral part of due diligence when investing in Allogene Therapeutics. Arie Belldegrun insider activity provides valuable insight into whether Allogene Therapeutics is net buyers or sellers over its current business cycle. Note, Allogene Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allogene Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Arie Belldegrun over three weeks ago Acquisition by Arie Belldegrun of 4710121 shares of Allogene Therapeutics subject to Rule 16b-3 | ||
Arie Belldegrun over a month ago Acquisition by Arie Belldegrun of 4710120 shares of Allogene Therapeutics subject to Rule 16b-3 |
Allogene Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2684) % which means that it has lost $0.2684 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5551) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.55. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 245.6 M, while Net Tangible Assets are likely to drop about 732.1 M.Similar Executives
Found 7 records | CHAIRMAN Age | ||
William Ringo | Sangamo Therapeutics | 70 | |
Daniel Lynch | Blueprint Medicines Corp | 60 | |
Perry Karsen | Intellia Therapeutics | 63 | |
John Mendlein | aTyr Pharma | 58 | |
Seth Rudnick | G1 Therapeutics | 69 | |
John Clarke | aTyr Pharma | 64 | |
James Mullen | Editas Medicine | 65 |
Management Performance
Return On Equity | -0.56 | ||||
Return On Asset | -0.27 |
Allogene Therapeutics Leadership Team
Elected by the shareholders, the Allogene Therapeutics' board of directors comprises two types of representatives: Allogene Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allogene. The board's role is to monitor Allogene Therapeutics' management team and ensure that shareholders' interests are well served. Allogene Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allogene Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
John DeYoung, Independent Director | ||
Franz Humer, Independent Director | ||
Timothy Moore, Executive Officer | ||
Rafael MD, Ex RD | ||
Joshua Kazam, Co-Founder, Director | ||
Geoffrey Parker, Executive CFO | ||
FACS FACS, CoFounder Chairman | ||
David Bonderman, Independent Director | ||
Susan Lundeen, Chief Officer | ||
Arie Belldegrun, Executive Chairman of the Board, Co-Founder | ||
David Chang, President CEO, Co-Founder, Director | ||
Veer Bhavnagri, G Officer | ||
Earl Esq, General Officer | ||
Christine Cassiano, Chief Officer | ||
Owen Witte, Independent Director | ||
Yinlin Chen, Senior Finance | ||
MD FACS, CoFounder Chairman | ||
Alison Moore, Chief Technical Officer | ||
David JD, Secretary | ||
Eric Schmidt, Chief Officer | ||
Deborah Messemer, Independent Director | ||
Todd Sisitsky, Independent Director | ||
Stephen Cheng, Chief Officer | ||
Barbra Sasu, Chief Scientific Officer |
Allogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allogene Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.56 | ||||
Return On Asset | -0.27 | ||||
Current Valuation | 231.48 M | ||||
Shares Outstanding | 169.09 M | ||||
Shares Owned By Insiders | 22.44 % | ||||
Shares Owned By Institutions | 73.66 % | ||||
Number Of Shares Shorted | 30.62 M | ||||
Price To Earning | (3.30) X | ||||
Price To Book | 1.25 X | ||||
Price To Sales | 6,764 X |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
0.87 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against Allogene Stock
0.51 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.55) | Return On Assets (0.27) | Return On Equity (0.56) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.